The USA FTC pointed out that the three major pharmaceutical benefit management Institutions in the USA have significantly increased their prices.

On January 15, Gelonghui reported that the USA Federal Trade Commission (FTC) stated on Tuesday that the three major Pharmaceutical benefits management Institutions in the USA, including UnitedHealth Group, CVS Health, and Cigna, significantly raised the prices of certain medications in their pharmacies, including those for heart disease, cancer, and HIV. The Commission noted that from 2017 to 2022, UnitedHealth's Optum, CVS Health's CVS Caremark, and Cigna's Express Scripts increased the prices in their pharmacies several times to dozens of times, resulting in net income exceeding Pharmaceutical procurement costs by 7.3 billion dollars.

Gelonghui Finance10:08

Sector Update: Health Care Stocks Slide Late Afternoon

MT Newswires04:54

PBMs Generated Billions in Drug Markups, FTC Says -- Barrons.com

Barron's04:34

Is The Cigna Group (CI) the Best Safe Dividend Stock for 2025?

Yahoo Finance04:04

FTC Finds PBMs Excessively Marked up Prices on Specialty Drugs

Seeking Alpha01:52

Major US Pharmacy Benefit Managers Inflated Drug Prices for Over $7.3 Billion Gain, FTC Says

MT Newswires00:59